Evaluation of the effect of oral monte locust in the treatment of acute asthma in children

Assessing the Effect of Oral Monte Locasta Compared with Pharmacology in Asthma Attacks, In addition to the common treatment of asthma attacks as a two-course, an accident in children aged 1-14 years with asthma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200412047048N1

Enrollment

100

Registered

2020-06-15

Start date

2019-02-04

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: In the intervention group, which included children aged 1-14 years with a diagnosis of asthma attack, Monte Lukast 5 mg / 4.5 tablets for children under 1 year of age and one complete

Eligibility

Sex/Gender

All

Age

1 Years to 14 Years

Inclusion criteria

Inclusion criteria: All patients aged 1-14 years who are confirmed based on history and examination for asthma attack

Exclusion criteria

Exclusion criteria: Those with a history of taking corticosteroids or montelukast for the past ten days All patients who developed a diagnosis other than asthma, such as pneumonia or bronchiolitis

Design outcomes

Primary

Measure	Time frame
Asthma. Timepoint: At the beginning of the patient's visit, 1,4,8,24,48 hours after the intervention and one week after discharge from the hospital. Method of measurement: Patient scoreboard.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoomeh Sobhani

Tehran University of Medical Sciences

masoomeh.sbh@gmail.com+98 21 4405 0743

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026